Q3week Carboplatin With Weekly Abraxaneä And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer
See above brief summary
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
pathological response rates at surgery
at surgery approximately 5 months after initail treatment
No
William Sikov, MD
Principal Investigator
Brown University
United States: Institutional Review Board
BrUOG-BR-211A
NCT00723125
September 2008
December 2016
Name | Location |
---|---|
Bridgeport Hospital | Bridgeport, Connecticut 06610 |
The Miriam Hospital | Providence, Rhode Island 02903 |
Women and Infants | Providence, Rhode Island |
Yale Smilow Cancer Center | New Haven, Connecticut 06519 |
Rhode Island Hsopital | Providence, Rhode Island 02903 |